PT - JOURNAL ARTICLE AU - Cowling, Benjamin J. AU - Wong, Sook-San AU - Santos, Jefferson J. S. AU - Touyon, Lisa AU - Ort, Jordan AU - Ye, Naiqing AU - Kwok, Natalie K. M. AU - Ho, Faith AU - Cheng, Samuel M. S. AU - Ip, Dennis K. M. AU - Peiris, Malik AU - Webby, Richard J. AU - Wilson, Patrick C. AU - Valkenburg, Sophie A. AU - Tsang, John S. AU - Leung, Nancy H. L. AU - Hensley, Scott E. AU - Cobey, Sarah TI - Preliminary findings from the Dynamics of the Immune Responses to Repeat Influenza Vaccination Exposures (DRIVE I) Study: a Randomized Controlled Trial AID - 10.1101/2024.05.16.24307455 DP - 2024 Jan 01 TA - medRxiv PG - 2024.05.16.24307455 4099 - http://medrxiv.org/content/early/2024/05/17/2024.05.16.24307455.short 4100 - http://medrxiv.org/content/early/2024/05/17/2024.05.16.24307455.full AB - Background Studies have reported that repeated annual vaccination may influence the effectiveness of the influenza vaccination in the current season. The mechanisms underlying these differences are unclear but might include “focusing” of the adaptive immune response to older strains.Methods We established a 5-year randomized placebo-controlled trial of repeated influenza vaccination (Flublok, Sanofi Pasteur) in adults 18-45 years of age. Participants were randomized equally between five groups, with planned annual receipt of vaccination (V) or saline placebo (P) as follows: P-P-P-P-V, P-P-P-V-V, P-P-V-V-V, P-V-V-V-V, or V-V-V-V-V. Serum samples were collected each year just before vaccination and after 30 and 182 days. A subset of sera were tested by hemagglutination inhibition assays, focus reduction neutralization tests and enzyme-linked immunosorbent assays against vaccine strains.Results From 23 October 2020 through 11 March 2021 we enrolled and randomized 447 adults. We selected sera from 95 participants at five timepoints from the first two study years for testing. Among vaccinated individuals, antibody titers increased between days 0 and 30 against each of the vaccine strains, with substantial increases for first-time vaccinees and smaller increases for repeat vaccinees, who had higher pre-vaccination titers in year 2. There were statistically significant reductions in the proportion of participants achieving a four-fold greater rise in antibody titer for the repeat vaccinees for A(H1N1), B/Victoria and B/Yamagata, but not for influenza A(H3N2). There were no statistically significant differences between groups in geometric mean titers at day 30 or the proportions of participants with antibody titers ≥40 at day 30 for any of the vaccine strains.Conclusions In the first two years, repeat vaccinees and first-time vaccinees had similar post-vaccination geometric mean titers to all four vaccine strains, indicative of similar levels of clinical protection. The vaccine strains of A(H1N1) and A(H3N2) were updated in year 2, providing an opportunity to explore antigenic distances between those strains in humans in subsequent years.Competing Interest StatementB.J.C. consults for AstraZeneca, Fosun Pharma, GlaxoSmithKline, Haleon, Moderna, Novavax, Pfizer, Roche and Sanofi Pasteur. S.C. has consulted for Seqirus. S.E.H. is a co-inventor on patents that describe the use of nucleoside-modified mRNA as a vaccine platform. S.E.H reports receiving consulting fees from Sanofi, Pfizer, Lumen, Novavax, and Merck. The authors report no other potential conflicts of interest.Clinical TrialClinicaltrials.gov: NCT04576377Funding StatementThis project was supported by federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services (grant no. U01 AI153700 and contract nos. 75N93021C00015 and 75N93021C00016), and the Theme-based Research Scheme (Project No. T11-712/19-N) of the Research Grants Council of the Hong Kong SAR Government. BJC is supported by an RGC Senior Research Fellowship (grant number: HKU SRFS2021-7S03).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study protocol was approved by the Institutional Review Boards of the University of Hong Kong (ref: UW19-551) and of the University of Chicago Biological Sciences Division (ref: IRB20-0217).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors